These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9665183)

  • 1. Cellular resistance mechanisms with impact on the therapy of multiple myeloma.
    Gieseler F; Nüssler V
    Leukemia; 1998 Jul; 12(7):1009-12. PubMed ID: 9665183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular resistance mechanisms with impact on the therapy of multiple myeloma.
    Gieseler F; Nüssler V
    Leukemia; 1997 Dec; 11 Suppl 5():S1-4. PubMed ID: 9436930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenes in multiple myeloma: point mutation of N-ras.
    Paquette RL; Berenson J; Lichtenstein A; McCormick F; Koeffler HP
    Oncogene; 1990 Nov; 5(11):1659-63. PubMed ID: 2267133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumour suppressor genes and can be monitored by the oncoprotein phenotype.
    Pope B; Brown R; Luo XF; Gibson J; Joshua D
    Leuk Lymphoma; 1997 May; 25(5-6):545-54. PubMed ID: 9250826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the biology and treatment of multiple myeloma.
    Varterasian ML
    Curr Opin Oncol; 1999 Jan; 11(1):3-8. PubMed ID: 9914870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptotic signaling in multiple myeloma: therapeutic implications.
    Chauhan D; Hideshima T; Anderson KC
    Int J Hematol; 2003 Aug; 78(2):114-20. PubMed ID: 12953804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCL-X expression in multiple myeloma: possible indicator of chemoresistance.
    Tu Y; Renner S; Xu F; Fleishman A; Taylor J; Weisz J; Vescio R; Rettig M; Berenson J; Krajewski S; Reed JC; Lichtenstein A
    Cancer Res; 1998 Jan; 58(2):256-62. PubMed ID: 9443402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular aspects of multiple myeloma.
    Kastrinakis NG; Gorgoulis VG; Foukas PG; Dimopoulos MA; Kittas C
    Ann Oncol; 2000 Oct; 11(10):1217-28. PubMed ID: 11106109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The oncoprotein phenotype of plasma cells from patients with multiple myeloma.
    Brown RD; Pope B; Luo XF; Gibson J; Joshua D
    Leuk Lymphoma; 1994 Dec; 16(1-2):147-56. PubMed ID: 7696921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Bcl-2 for the treatment of multiple myeloma.
    Touzeau C; Maciag P; Amiot M; Moreau P
    Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma.
    Iyer R; Ding L; Batchu RB; Naugler S; Shammas MA; Munshi NC
    Leuk Res; 2003 Jan; 27(1):73-8. PubMed ID: 12479855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance in multiple myeloma: novel therapeutic targets within the malignant clone.
    Pilarski LM; Mant MJ; Belch AR
    Leuk Lymphoma; 1999 Jan; 32(3-4):199-210. PubMed ID: 10037018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of thalidomide in the treatment of multiple myeloma].
    Mikala G; Jákó J; Vályi-Nagy I
    Orv Hetil; 2001 Aug; 142(33):1789-98. PubMed ID: 11573449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of P-glycoprotein in drug resistance in multiple myeloma.
    Abraham J; Salama NN; Azab AK
    Leuk Lymphoma; 2015 Jan; 56(1):26-33. PubMed ID: 24678978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
    Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
    Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistance in multiple myeloma: approaches to circumvention.
    Dalton WS; Jove R
    Semin Oncol; 1999 Oct; 26(5 Suppl 13):23-7. PubMed ID: 10528891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular analysis of multiple myeloma cells].
    Yasuga Y; Hirosawa S
    Nihon Rinsho; 1995 Mar; 53(3):564-7. PubMed ID: 7699886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma.
    Thomas AL; Coarfa C; Qian J; Wilkerson JJ; Rajapakshe K; Krett NL; Gunaratne PH; Rosen ST
    Nucl Recept Signal; 2015; 13():e006. PubMed ID: 26715915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in biology and therapy of multiple myeloma.
    Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
    Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.
    Furukawa Y; Kikuchi J
    Int J Hematol; 2016 Sep; 104(3):281-92. PubMed ID: 27411688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.